Strategic Performance and Market Dynamics
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Performance was driven by the durability of the recurring Autoship model, which reached 84.4% of total net sales and grew over 10% year-over-year.
Management attributed record profitability to structural drivers including sponsored ads expansion, favorable product mix into health, and supply chain efficiencies from automation.
A weakening consumer environment in the latter part of Q1 led to modest pressure on premiumization and product attach rates, particularly in discretionary categories.
The company is successfully gaining market share as consumers prioritize value and reliability, with Chewy’s absolute clicks increasing mid-single-digits despite broader industry impression declines.
Strategic positioning in pet health was bolstered by the acquisition of Modern Animal, aiming to capture a larger share of the $54 billion pet health TAM.
Operational leverage is being realized through AI integration across customer service, pharmacy, and fulfillment, targeting low tens of millions in savings for fiscal 2026.
Fiscal 2026 Outlook and Strategic Assumptions
Full-year net sales guidance was revised to $13.40 billion–$13.55 billion to reflect a more conservative view of the consumer environment and muted impact from growth initiatives.
Active customer additions are now expected to trend toward the lower end of the 150,000 to 250,000 range per quarter due to challenged new customer acquisition trends.
Management maintains its 10% long-term adjusted EBITDA margin target, supported by structural margin expansion that does not rely on outsized industry growth or pricing inflation.
The company expects to operate approximately 60 vet clinics by the end of fiscal 2026, with steady-state revenue contribution approaching $290 million.
A $600 million Term Loan B transaction was launched to evolve the capital structure, providing flexibility for M&A and shareholder returns while targeting net leverage below 2x.
Structural Changes and Risk Factors
The acquisition of Modern Animal adds 29 clinics and is expected to be adjusted EBITDA dollar neutral in 2026, though it will act as a modest margin rate drag.
Q2 gross margin is expected to contract modestly year-over-year due to difficult comparisons against nonrecurring MAP pricing benefits realized in fiscal 2025.
Elevated fuel surcharges passed on by carrier partners are expected to represent a mid-single-digit million dollar headwind in the second quarter.
Management flagged a short-term NSPAC headwind as consumers become more discerning and deliberate in discretionary spending decisions.
